The Antioxidant Effects of the Flavonoids Rutin and Quercetin Inhibit Oxaliplatin-Induced Chronic Painful Peripheral Neuropathy

Molecular Pain - 2013
María Isabel de Azevedo1, Adriana Lenho de Figueiredo Pereira1, R.B. Nogueira2, Francisco Felippe De Araújo Rolim2, Gerly Anne Castro Brito3, Deysi Viviana Tenazoa Wong2, Roberto César Pereira Lima‐Júnior2, Ronaldo de Albuquerque Ribeiro2, Mariana Lima Vale1
1Medical Sciences Post-Graduation, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil
2Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, CE, Brazil
3Department of Morphology, Federal University of Ceará, Fortaleza, Brazil

Tóm tắt

Background Oxaliplatin, the third-generation platinum compound, has evolved as one of the most important therapeutic agents in colorectal cancer chemotherapy. The main limiting factor in oxaliplatin treatment is painful neuropathy that is difficult to treat. This side effect has been studied for several years, but its full mechanism is still inconclusive, and effective treatment does not exist. Data suggest that oxaliplatin's initial neurotoxic effect is peripheral and oxidative stress-dependent. A spinal target is also suggested in its mechanism of action. The flavonoids rutin and quercetin have been described as cell-protecting agents because of their antioxidant, antinociceptive, and anti-inflammatory actions. We proposed a preventive effect of these agents on oxaliplatin-induced painful peripheral neuropathy based on their antioxidant properties. Methods Oxaliplatin (1 mg/kg, i.v.) was injected in male Swiss mice, twice a week (total of nine injections). The development of sensory alterations, such as thermal and mechanical allodynia, was evaluated using the tail immersion test in cold water (10°C) and the von Frey test. Rutin and quercetin (25–100 mg/kg, i.p.) were injected 30 min before each oxaliplatin injection. The animals' spinal cords were removed for histopathological and immunohistochemical evaluation and malondialdehyde assay. Results Oxaliplatin significantly increased thermal and mechanical nociceptive response, effects prevented by quercetin and rutin at all doses. Fos immunostaining in the dorsal horn of the spinal cord confirmed these results. The oxidative stress assays mainly showed that oxaliplatin induced peroxidation in the spinal cord and that rutin and quercetin decreased this effect. The flavonoids also decreased inducible nitric oxide synthase and nitrotyrosine immunostaining in the dorsal horn of the spinal cord. These results suggest that nitric oxide and peroxynitrite are also involved in the neurotoxic effect of oxaliplatin and that rutin and quercetin can inhibit their effect in the spinal cord. We also observed the preservation of dorsal horn structure using histopathological analyses. Conclusions Oxaliplatin induced painful peripheral neuropathy in mice, an effect that was prevented by rutin and quercetin. The mechanism of action of oxaliplatin appears to be, at least, partially oxidative stress-induced damage in dorsal horn neurons, with the involvement of lipid peroxidation and protein nitrosylation.

Từ khóa


Tài liệu tham khảo

Chu E, 2004, The Clinical Use of Oxaliplatin: Case Studies and Roundtable Discussion., 109

Argyriou AA, 2008, Cancer Treat Rev, 34, 368, 10.1016/j.ctrv.2008.01.003

De Gramont A, 2000, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938

Van Cutsem E, 2002, Best Tract Res Clin Gastroenterol, 16, 319, 10.1053/bega.2002.0288

Goldberg RM, 2003, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046

Hurwitz HI, 2003, Clin Adv Hematol Oncol, 7, 404

Authier N, 2009, Neurotherapeutics, 6, 620, 10.1016/j.nurt.2009.07.003

Joseph EK, 2008, J Pain, 9, 463, 10.1016/j.jpain.2008.01.335

Kaley TJ, 2009, Br J Haematol, 145, 3, 10.1111/j.1365-2141.2008.07558.x

Paice JA, 2009, Semin Oncol Nurs, 25, S8, 10.1016/j.soncn.2009.03.013

Dworkin RH, 2007, Pain, 132, 237, 10.1016/j.pain.2007.08.033

Jamieson SM, 2005, Cancer Chemother Pharmacol, 56, 391, 10.1007/s00280-004-0953-4

Harborne JB, 1986, Prog Clin Biol Res, 213, 15

Havsteen B, 1983, Biochem Pharmacol, 32, 1141, 10.1016/0006-2952(83)90262-9

Morand C, 2000, Biofactors, 12, 169, 10.1002/biof.5520120127

Agarwal OP, 1982, Agents Actions, 12, 298, 10.1007/BF01965393

Delia Loggia R, 1986, Chamomilla recutita. Prog in Clin and Biol Res, 213, 481

Ferrandiz ML, 1991, Agents Actions, 32, 283, 10.1007/BF01980887

Emim JAS, 1994, J Pharm Pharmacol, 46, 118, 10.1111/j.2042-7158.1994.tb03753.x

Di Carlo G, 1999, Life Sci, 65, 337, 10.1016/S0024-3205(99)00120-4

Ling B, 2007, Pain, 128, 225, 10.1016/j.pain.2006.09.016

Le Bars D, 2001, Pharmacol Rev, 53, 597

Kovács KJ, 2008, J Neuroendocrinal, 20, 665, 10.1111/j.1365-2826.2008.01734.x

Herdegen T, 1995, Prog Brain Res, 104, 299, 10.1016/S0079-6123(08)61797-5

Harris JA, 1998, Brain Res Bull, 45, 1, 10.1016/S0361-9230(97)00277-3

Bullitt E, 1992, Brain Res, 580, 172, 10.1016/0006-8993(92)90941-2

Eastman A, 1987, Pharmacol Ther, 34, 155, 10.1016/0163-7258(87)90009-X

Windebank AJ, 2008, J Peripher Nerv Syst, 13, 27, 10.1111/j.1529-8027.2008.00156.x

Podratz JL, 2011, Neurobiol Dis, 41, 661, 10.1016/j.nbd.2010.11.017

10.1097/00004647-200109000-00005

Xiao WH, 2012, Neuroscience, 17, 194, 10.1016/j.neuroscience.2011.12.023

Di Cesare Mannelli L, 2013, Free Radic Biol Med, 31, 143, 10.1016/j.freeradbiomed.2013.03.019

Di Cesare Mannelli L, 2012, J Pain, 13, 276, 10.1016/j.jpain.2011.11.009

Tall JM, 2004, Clin J Pain, 20, 19, 10.1097/00002508-200401000-00005

Rice-Evans CA, 1995, Free Radic Res, 22, 375, 10.3109/10715769509145649

Ansari MA, 2009, J Nutr Biochem, 20, 269, 10.1016/j.jnutbio.2008.03.002

Ishige K, 2001, Free Radic Biol Med, 30, 433, 10.1016/S0891-5849(00)00498-6

Sanders RA, 2001, J Biochem Mol Toxicol, 15, 143, 10.1002/jbt.11

Singh A, 2003, Free Radic Res, 37, 1245, 10.1080/10715760310001616014

Alvarez B, 2003, Amino Acids, 25, 295, 10.1007/s00726-003-0018-8

Kumar A, 2010, Neurosci Res, 66, 271, 10.1016/j.neures.2009.11.009

Krol W, 1995, Biochem Pharmacol, 50, 1031, 10.1016/0006-2952(95)00237-T

Chen YC, 2001, J Cell Biochem, 82, 537, 10.1002/jcb.1184

Kuhlmann MK, 1998, Arch Toxicol, 72, 536, 10.1007/s002040050539

Middleton E, 1998, Adv Exp Med Biol, 439, 175, 10.1007/978-1-4615-5335-9_13

Zimmermann M, 1983, Pain, 16, 109, 10.1016/0304-3959(83)90201-4

Cunha TM, 2004, BrazJ Med Biol Res, 37, 401, 10.1590/S0100-879X2004000300018

Necker R, 1978, Pain, 4, 231, 10.1016/0304-3959(77)90135-X

Mihara M, 1978, Anal Biochem, 86, 271, 10.1016/0003-2697(78)90342-1

Thông tin
Thông tin xuất bản

Molecular Pain

Thông tin tác giả